Sign In
Buy APRE
$0.762
-0.0022 (-0.288%)
At Close: Jun 03, 2026
Presentation highlights early clinical activity from ACESOT-1051, including partial responses and stable disease in patients across multiple tumor types Manageable tolerability confirmed across cohort
Aprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should Know
01:02pm, Thursday, 21'st May 2026
Aprea Therapeutics (APRE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
06:30am, Wednesday, 13'th May 2026
DOYLESTOWN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the disco
Pre-Market Stock Futures: Futures are trading modestly higher after a blowout midweek rally spurred by reports that a peace agreement with Iran could be forthcoming soon and by incredible technology e
DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the dis
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
08:30am, Wednesday, 01'st Apr 2026
DOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the dis
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
08:01am, Monday, 30'th Mar 2026
Financing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Management and additional new and existing investors DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) --
Confirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined cancers Early clinical data suggest the potential of APR-1051 as a best-in-class WEE1 inhibitor Emer
Aprea Therapeutics (APRE) Projected to Post Quarterly Earnings on Tuesday
02:12am, Tuesday, 17'th Mar 2026
Aprea Therapeutics (NASDAQ: APRE - Get Free Report) will likely be releasing its Q4 2025 results before the market opens on Tuesday, March 24th. Analysts expect Aprea Therapeutics to post earnings of
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
08:00am, Monday, 16'th Mar 2026
DOYLESTOWN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the dis
Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars
02:02pm, Wednesday, 18'th Feb 2026
Aprea Therapeutics (NASDAQ: APRE) shares are trading higher on Wednesday as the company announced additional preliminary data from its ongoing Phase 1 trial of APR-1051, a WEE1 kinase inhibitor.
Tumor Shrinkage of 50% and significant CA-125 biomarker reduction observed at 220 mg dose level Patient experienced only Grade 1 adverse events Represents second patient with PR to harbor PPP2R1A mu
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
08:00am, Tuesday, 17'th Feb 2026
DOYLESTOWN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapie
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
08:30am, Thursday, 12'th Feb 2026
New patents granted in 2025 in Australia and Japan bolster global IP coverage for Aprea's WEE1 and ATR programs. Core patent families are expected to provide exclusivity into 2045.
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
08:30am, Wednesday, 04'th Feb 2026
Seasoned oncology drug development leader joins following early clinical proof-of-concept for WEE1 inhibitor, APR-1051 Seasoned oncology drug development leader joins following early clinical proof-of
